Spear Pharmaceutical’s Generic to Efudex sold to Mayne Pharmaceuticals
- Spear Pharma
- Nov 5, 2020
- 1 min read
Mayne Pharma Group Limited (“Mayne Pharma”) (ASX: MYX) has acquired generic Efudex® (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc. (“Spear”) for up to US$30.0 million
Product is immediately EPS accretive with an implied acquisition EBITDA multiple in the low single digits
Mayne Pharma will fund the acquisition from cash and undrawn debt
Comments